Creative Planning
ADMA icon

Creative Planning’s ADMA Biologics ADMA Stock Holding History

Creative Planning’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.24M Buy
148,519
+80,586
+119% +$735K ﹤0.01% 2469
2026
Q1 		$612K Buy
67,933
+5,394
+9% +$85.1K ﹤0.01% 2872
2025
Q4 		$1.14M Buy
62,539
+5,242
+9% +$88.3K ﹤0.01% 2178
2025
Q3 		$840K Sell
57,297
-17,712
-24% -$304K ﹤0.01% 2287
2025
Q2 		$1.37M Sell
75,009
-8,648
-10% -$176K ﹤0.01% 1610
2025
Q1 		$1.66M Buy
83,657
+36,459
+77% +$631K ﹤0.01% 1326
2024
Q4 		$809K Sell
47,198
-7,749
-14% -$146K ﹤0.01% 1819
2024
Q3 		$1.1M Buy
54,947
+18,800
+52% +$292K ﹤0.01% 1447
2024
Q2 		$404K Buy
36,147
+15,363
+74% +$129K ﹤0.01% 2117
2024
Q1 		$137K Buy
+20,784
New +$114K ﹤0.01% 2649
2023
Q3 		– Sell
-22,735
Closed -$83.9K – 2906
2023
Q2 		$83.9K Sell
22,735
-5,820
-20% -$21.6K ﹤0.01% 2377
2023
Q1 		$94.5K Buy
28,555
+492
+2% +$1.7K ﹤0.01% 2270
2022
Q4 		$109K Buy
28,063
+6,297
+29% +$19.4K ﹤0.01% 2133
2022
Q3 		$53K Buy
+21,766
New +$52.2K ﹤0.01% 2117

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Creative Planning's ADMA Position: Q2 2026 in Review

Creative Planning increased its ADMA Biologics (ADMA) stake by 119% in Q2 2026, buying an estimated $735K and bringing the position to 148,519 shares worth $1.24M. The position accounts for ﹤0.01% of the portfolio, ranked #2469.

Creative Planning first reported a position in ADMA in Q3 2022 and has held it in 14 quarters since. The position peaked at $1.66M in Q1 2025. 323 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Creative Planning held 148,519 shares of ADMA Biologics worth $1.24M as of Q2 2026.
  • Creative Planning bought 80,586 ADMA Biologics shares in Q2 2026, an estimated $735K.
  • ADMA Biologics made up ﹤0.01% of Creative Planning's portfolio in Q2 2026, its #2469 holding.
  • Creative Planning first reported a position in ADMA Biologics in Q3 2022 and has held it in 14 quarters since.
  • Creative Planning's ADMA Biologics position peaked at $1.66M in Q1 2025.
  • 323 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Creative Planning's 13F filing for Q2 2026, filed 13 Aug 2026.